+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Nano Biotechnology Market Size was valued at USD 5.2 Billion in 2022. The Nano Biotechnology market industry is projected to grow from USD 5.68 Billion in 2023 to USD 11.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.70% during the forecast period (2023 - 2032). Increased need for innovative medical innovations, increased demand for immediate disease treatment, and increased funding for research and development, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The advancements in nanotechnology have had a significant impact on the growth and development of the nanobiotechnology market. Nanotechnology is the study of how to control and manipulate materials at the nanoscale, which typically falls between 1 and 100 nanometers. At this size, materials exhibit unique characteristics and behaviors that can be taken advantage of for a number of biotechnological uses. One of the primary ways that advancements in nanotechnology are influencing the market is the production of novel nanomaterials. Now that nanoparticles can be accurately created, their size, shape, surface properties, and composition can all be carefully controlled. With this level of control, it is possible to develop nanoparticles with particular properties and the ability to interact molecularly with biological systems. To precisely bind to certain cells or tissues, for example, targeting ligands or antibodies can be added to nanoparticles, enabling tailored medication administration or imaging. The ability to produce nanoparticles with desired properties has revolutionized drug delivery techniques. For protection and controlled release, drugs can be affixed to nanoparticle surfaces or enclosed within their structures. This enables the targeted application of therapies to specific cells or tissues, minimizing adverse effects and increasing the therapeutic benefit. One biological barrier that nanoparticles can overcome is the blood-brain barrier, which makes it simpler to transport drugs to previously inaccessible areas.
Nanotechnology advancements have also led to the creation of nanosensors and nanodevices, which have a significant impact on monitoring and diagnostics. For identifying and measuring specific biomarkers or substances, nanosensors have high sensitivity and selectivity. By integrating into wearable technology, lab-on-a-chip platforms, or implanted sensors, they offer real-time monitoring of a wide range of physiological indicators or disease markers. This has the potential to transform illness diagnosis through early detection and intervention. Nanotechnology has made significant strides in two other sectors, including tissue engineering and regenerative medicine. Researchers have developed nanoscale scaffolds and matrices that imitate the extracellular matrix (ECM) found naturally in tissues. These scaffolds can support cell structure, promote cell adhesion, proliferation, and differentiation, and help in tissue regeneration. Additionally, nanoparticles can be used to distribute bioactive substances, growth factors, or stem cells to help in tissue regeneration and repair.
The integration of nanotechnology with fields including biology, chemistry, and engineering has also stimulated interdisciplinary study and collaboration. Innovative ideas and ground-breaking advances in nanobiotechnology have resulted from this convergence of knowledge. Through collaborative efforts between academic institutions, research organizations, and industry partners, the development and translation of nanotechnology-based innovations into practical applications have been accelerated. Furthermore, advances in nanotechnology are consistent with the growing demand for personalized care. Personalizing a patient's medical treatment in accordance with their particular genetic, molecular, and clinical characteristics is the aim of personalised medicine. Nanotechnology enables molecular level targeted and exact treatments, enabling individualized medication administration, diagnosis, and monitoring. Nanoscale instruments and devices can be developed to interact with specific cells, tissues, or chemicals, allowing for more accurate and individualized treatments.
Government funding and support have also greatly spurred advances in nanotechnology. Governments all around the world are aware of the promise of nanotechnology and its uses in a number of industries, including biotechnology. They support the research and development efforts in the field through financing programs, grants, and research initiatives. By enhancing information sharing, resource access, and cooperative research initiatives, this aid promotes cooperation among governmental, commercial, and academic institutions. In conclusion, developments in nanotechnology have had a substantial impact on the market for nanobiotechnology. Due to the creation of cutting-edge drug delivery systems, tissue engineering scaffolds, improved imaging techniques, and the ability to create nanomaterials with desired properties, the field of biotechnology has undergone a revolution. These advancements have enabled more targeted, personalized medicines, superior diagnostics and monitoring, and more efficient treatment. With ongoing research and development, nanotechnology will continue to fuel growth and innovation in the nano biotechnology sector, creating new opportunities and applications in a variety of industries. Thus, driving the Nano Biotechnology market revenue.
The global Nano Biotechnology market segmentation, based on Application includes Pharmaceuticals, Medical devices, Medical Research, Food and Agriculture. With 45.65% of market revenue coming from the pharmaceuticals sector, this segment led the market. Innovative approaches to medicine delivery, formulation, and development are provided by nanobiotechnology.
The global Nano Biotechnology market segmentation, based on Therapeutics, includes Dental Therapies, Cardiac Therapies, and Orthopedic Therapies. The category with the highest revenue (51.6%) was Orthopaedic Therapies. Osteoarthritis, joint injuries, and fractures are all included in the diagnosis, treatment, and rehabilitation of musculoskeletal problems by orthopaedic therapy.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Nano Biotechnology Market dominated this market in 2022 (45.80%). This proportion can be attributed to significant financial investments in R&D projects, reputable research institutes for product development, government efforts to improve the healthcare system, and growing end-user demand. Further, In the North American area, the U.S. Nano Biotechnology market had the biggest market share, while the Canada Nano Biotechnology market had the quickest rate of expansion.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Nano Biotechnology market accounts for the second-largest market share. The strong consumer demand for items with cutting-edge technology and reputable R&D facilities are the primary factors propelling the growth of the nanobiotechnology market. Further, In the European region, the German Nano Biotechnology market had the biggest market share, and the U.K. Nano Biotechnology market had the quickest rate of growth.
The Asia-Pacific Nano Biotechnology Market is expected to grow at the fastest CAGR from 2023 to 2032. Government R&D spending is rising, supporting the development of nanotechnology-based gadgets and its quick adoption in diagnostic procedures. Moreover, In the Asia-Pacific region, the Indian Nano Biotechnology market had the quickest rate of growth while China's Nano Biotechnology market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Nano Biotechnology market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Nano Biotechnology sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Nano Biotechnology industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Nano Biotechnology sector. Major players in the Nano Biotechnology market, including Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nanobiotix(France), Dabur Pharma (India), are attempting to increase market demand by investing in research and development operations.
Ablynx NV (Ablynx), a Sanofi subsidiary, is a biopharmaceutical company that specializes in developing Nanobodies, distinct therapeutic proteins made from single-domain antibody fragments. Oncology, immuno-oncology, inflammation, and other significant disease areas are among the company's portfolio of Nanobody-based therapeutic programs. Using the company's unique Nanobody platform, novel biological medicines with the potential to treat a range of human illnesses can be developed quickly and produced in large quantities. The company has significant research relationships to numerous significant pharmaceutical companies, including Merck, Novartis, and Boehringer Ingelheim. Ablynx's corporate headquarters are in Ghent, Belgium.
Celgene Corp (Celgene), a part of Bristol-Myers Squibb Co., is an integrated biopharmaceutical company that discovers, develops, produces, and disseminates novel gene and protein regulation medicines for the treatment of cancer and immune-inflammatory disorders. Its major product range includes, among other things, Thalomid (thalidomide), Revlimid (lenalidomide), Pomalyst (pomalidomide), and Abraxane (paclitaxel albumin-bound particles for injectable solution). The company sells its products throughout Europe, the Americas, the Middle East, and Asia-Pacific through its own sales teams and distributors. The company's headquarters are in the US city of Summit, New Jersey.
· Ablynx (Belgium),
· Nami Therapeutics (US)
· Celgene Corporation (US)
· Nanophase Technologies Corporation (US)
· Sigma-Aldrich (US)
· SkyePharma Pharmaceuticals (France)
· Nanobiotix(France)
· Dabur Pharma (India)
May 2021: Nanobiotix (France) and LianBio (China) teamed together to create and promote a potential first-in-class radioenhancer nbtxr3 across tumor types and therapeutic combinations in China and other Asian markets.
June 2018: The creation and promotion of the potentially first-in-class radioenhancer nbtxr3 by Nanobiotix (France) and LianBio (China) will help China and other Asian markets.
· Pharmaceuticals
· Medical Devies
· Medical Research
· Food and Agriculture
· Dental Therapies
· Cardiac Therapies
· Orthopedic Therapies
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 5.2 Billion |
|
Market Size 2023 |
USD 5.68 Billion |
|
Market Size 2032 |
USD 11.8 Billion |
|
Compound Annual Growth Rate (CAGR) |
9.70% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Distribution Channel, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nanobiotix(France), Dabur Pharma (India) |
|
Key Market Opportunities |
Government support and funding |
|
Key Market Dynamics |
Advancements in nanotechnology Increasing demand for personalized medicine |
The global Nano Biotechnology market size was valued at USD 5.2 Billion in 2022.
The global market is projected to grow at a CAGR of 9.70% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company.
The beverage category dominated the market in 2022.
The store based had the largest share in the global market.
Report Code :
RL65328
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst